THERESA-5 Study
- Conditions
- Acute hemorrhoids
- Registration Number
- RPCEC00000191
- Lead Sponsor
- Center for Genetic Engineering and Biotechnology (CIGB).
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1500
1) Compliance with the diagnostic criteria (fluxion and / or thrombosed hemorrhoid anal pain characterized by sudden onset, with tumors of variable size and appearance and can be red-violet color, usually associated with significant swelling).
2) Age = 18 years.
3) Anal pain (of any degree of intensity) and / or bleeding at the time of inclusion in the study. 4) Voluntariness of the patient by signing the informed consent.
1. Active internal bleeding (<3 weeks) or other conditions where there is risk of major bleeding, or would be unwieldy because of its location.
2. acute diarrheal disease in the past 12 hours.
3. History of allergy to streptokinase, thiomersal, salicylates (including aspirin), or any ingredients of the formulations under study.
4. Pregnancy or lactation at the time of inclusion in the study.
5. Mental incapacity to give consent clearly and act accordingly to the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.